Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
April 11, 2023 07:12 AM EDT
Deals

Ex­tend­ed FTC re­view adds wrin­kle to Sanofi's $2.9B Proven­tion Bio buy­out

Amber Tong

Sanofi is ex­tend­ing the dead­line for its $2.9 bil­lion ac­qui­si­tion of Proven­tion Bio to give an­titrust reg­u­la­tors more time to re­view the deal.

The French …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times